Hong Jae Chon, MD, PhD

Articles by Hong Jae Chon, MD, PhD

Phase 1 Study of BGB-B2033 (GPC3 x 4-1BB Bispecific Antibody) Monotherapy: First Disclosure of Dose Optimization and Dose Escalation Update in Advanced Hepatocellular Carcinoma

ByHong Jae Chon, MD, PhD

November 3rd 2026

Rapid readout: BGB-233 shows strong responses and good safety in heavily pretreated liver cancer, with 36% ORR at 450 mg and Phase 3 planned.

Latest Updated Articles

Trending on OncLive

Camizestrant Approval Paves the Way for ctDNA-Guided Switching in Emergent ESR1-Mutated HR+/HER2– Advanced Breast Cancer

Dr Hansen on the Potential Role of GPRC5D-Targeted CAR T-Cell Therapy in Myeloma

Belzutifan Plus Lenvatinib Raises New Sequencing Questions in Advanced RCC

Cross Currents: Dual EGFR/MET Inhibition in EGFR-Mutated NSCLC

Study Reveals Distinct Cellular and Genetic Differences in Colorectal Cancer in Younger Patients